openPR Logo
Press release

Global Renal Artery Stenosis Treatment Market Scenario Highlighting Major Drivers & Trends, 2018-2028 / Abbott Laborites, Pfizer Inc., Novartis AG, Merck & Company, Inc., AstraZeneca plc., Johnson and Johnson, Eli Lilly and Company, Sanofi SA, Bayer AG, G

01-08-2019 01:13 PM CET | Health & Medicine

Press release from: Fact.MR

Global Renal Artery Stenosis Treatment Market Scenario

The growing prevalence of atherosclerosis is expected to be a major factor driving the growth of the Renal Artery Stenosis Treatment Market over the forecast period. The worldwide prevalence of atherosclerotic renal artery stenosis is 0.5% in the overall population, and 5-4% among patients with chronic kidney disease. Increasing peripheral atrial disease and cholesterol problems are the other factors expected to boost the demand for renal artery stenosis treatment drugs. Inactive lifestyles, unhealthy eating habits, irregular eating timings, and lack of exercise are attributed to the growing prevalence of renal artery stenosis.  

Claim Sample Report For FREE: https://www.factmr.com/connectus/sample?flag=S&rep_id=1489

Increasing hypertension problems among the general population and increasing older population are other factors expected to fuel the growth of the renal artery stenosis treatment market. Increasing diagnosis rates due to screening programs, favorable Medicare policies, increasing and healthcare expenditures are other reasons for the growth of the renal artery stenosis treatment market. The side effects associated with some renal artery stenosis treatment medications and no proper treatment available for renal artery stenosis associated with fibromuscular dysplasia are some of the factors expected to restrain the renal artery stenosis treatment market

Renal artery stenosis is the narrowing of the renal artery that carries blood to the kidneys. The narrowing of the renal artery obstructs blood flow, resulting in renovascular hypertension, high blood pressure, and kidney damage. Atherosclerosis and fibromuscular dysplasia are the major causes of renal artery stenosis. Atherosclerosis is the most common cause of renal artery stenosis in the older age group. 90% renal artery stenosis is caused by atherosclerosis. Atherosclerosis is a disease in which the inside of the artery narrows due to plaque buildup of cholesterol and fats. Atherosclerosis is associated with the narrowing, clogging, and hardening of the renal arteries. Fibromuscular dysplasia is commonly seen in the young age group, and predominantly affects women. Fibromuscular dysplasia is a rare cause of renal artery stenosis, in which the arterial wall cells undergo abnormal growth. Chronic kidney disease, coronary artery disease, peripheral vascular disease, and stroke are the possible complications associated with renal artery stenosis. For renal artery stenosis treatment, doctors mostly prescribe medication to lower cholesterol levels and high blood pressure. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are the most common blood pressure lowering medications used for renal artery stenosis treatment. Diuretic, beta blockers, and calcium channel blockers are other common drugs used for renal artery stenosis treatment.

Request Full Report with TOC: https://www.factmr.com/report/1489/renal-artery-stenosis-treatment-market

Renal Artery Stenosis Treatment Market: Drivers and Restraints

The global market for renal artery stenosis treatment is expected to witness moderate growth over the forecast period. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers Renal Artery Stenosis Treatment are expected to contribute major revenue share in the renal artery stenosis treatment market. Among both of the indications, the atherosclerosis segment is expected to lead in the global renal artery stenosis treatment market over the forecast period. The retail pharmacies distribution channel segment in is expected to contribute a high share in the global renal artery stenosis treatment market, as it is the most accessible channel and a majority of patients are recommended for outpatient treatment.

Renal Artery Stenosis Treatment Market: Regional Outlook

Geographically, the global renal artery stenosis treatment market is segmented into America, Latin America, Europe, CIS & Russia, Asia Pacific excluding Japan (APEJ), Japan, and the Middle East and Africa (MEA). North America is expected to be the dominant market in the global renal artery stenosis treatment market, owing to the high prevalence of atherosclerosis among the older population. Europe Renal Artery Stenosis Treatment market is expected to have the second-largest share in the global renal artery stenosis treatment market throughout the forecast period, owing to high awareness regarding health-related problems and increasing healthcare screening programs. The renal artery stenosis treatment market in the Asia Pacific excluding Japan is expected to grow at a significant CAGR, due to increasing healthcare expenditure and increasing healthcare facilities.  

Renal Artery Stenosis Treatment Market: Key Players

Examples of some of the key players operating in the global renal artery stenosis treatment market are Abbott Laborites, Pfizer Inc., Novartis AG, Merck & Company, Inc., AstraZeneca plc., Johnson and Johnson, Eli Lilly and Company, Sanofi SA, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.

Ask Industry Expert about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=1489

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Renal Artery Stenosis Treatment Market Scenario Highlighting Major Drivers & Trends, 2018-2028 / Abbott Laborites, Pfizer Inc., Novartis AG, Merck & Company, Inc., AstraZeneca plc., Johnson and Johnson, Eli Lilly and Company, Sanofi SA, Bayer AG, G here

News-ID: 1479557 • Views:

More Releases from Fact.MR

Remote Control Market Projected to Reach US$ 42.1 Billion by 2034, Growing at a CAGR of 4.8%
Remote Control Market Projected to Reach US$ 42.1 Billion by 2034, Growing at a …
As of right now, estimates place the size of the global remote control market at a 4.8% compound annual growth rate (CAGR) over the following ten years, rising from US$ 26.4 billion in 2024 to US$ 42.1 billion by 2034. Sales of remote controls are expected to increase gradually between 2024 and 2034 as a result of product technical developments and market participants' calculated moves. Businesses have a rare chance to
Global SAP Cloud Platform Services Market is likely to reach a valuation of USD 6.5 Million by 2032
Global SAP Cloud Platform Services Market is likely to reach a valuation of USD …
Fact.MR recently conducted a study on the global SAP cloud platform services market is anticipated to surge from USD 443 million in 2022 to a staggering USD 7,000 million by 2032. This remarkable growth trajectory is projected to unfold at an exhilarating compound annual growth rate (CAGR) of 31% over the period spanning from 2022 to 2032. This analysis delves into pivotal trends shaping the market's growth trajectory. The report elucidates
Mobile Value Added Service Market is projected to rise at a CAGR of 14.9% through 2034
Mobile Value Added Service Market is projected to rise at a CAGR of 14.9% throug …
As per a recent study conducted by Fact.MR, a prominent provider of market research and competitive intelligence, the global Mobile Value Added Service Market is valued at approximately US$ 880.4 million in 2024. Forecasts indicate a robust compound annual growth rate (CAGR) of 14.9% through 2034, with the market anticipated to exceed a valuation of US$ 3,522.6 million by the end of that period. Intense competition among smartphone manufacturers has led
GMP Cell Banking Service Market value is projected to reach US$ 3,123.5 million by 2034
04-23-2024 | Health & Medicine
Fact.MR
GMP Cell Banking Service Market value is projected to reach US$ 3,123.5 million …
According to Fact.MR, a leading provider of market research and competitive intelligence, the global GMP Cell Banking Service Market is anticipated to reach approximately US$ 882.1 million by 2024. Over the period from 2024 to 2034, the market for GMP cell banking services is expected to witness a robust growth rate of 13.7%. The report further forecasts that the market will attain an overall valuation of US$ 3,123.5 million by

All 5 Releases


More Releases for Renal

Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period
Acute Renal Failure Epidemiology Insights to 2025
Publisher " Acute Renal Failure ARF Acute Kidney Injury - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Acute Renal Failure ARF Acute Kidney Injury in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Acute Renal Failure ARF Acute Kidney Injury prevalent or incident cases segmented by age, sex and subpopulations. The Report
Renal Insufficiency Market Vendor Growth Landscape 2025
Global Renal Insufficiency Market: Snapshot The demand for renal disease treatment products and therapies has been incrementing steadily in the past few years, owing to the prevalence of poor kidney functions among a vast population base across the world, especially in the Asia Pacific region, and increased government support. However, the participants of the global renal insufficiency market must take a note of weak competition among the marketed products for the
Acute Renal Failure - Pipeline Review, H1 2018
"The Report Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Acute Renal Failure Market Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2018, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)
Acute Renal Failure Epidemiology Insights to 2025
Publisher " Acute Renal Failure ARF Acute Kidney Injury - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Acute Renal Failure ARF Acute Kidney Injury in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Acute Renal Failure ARF Acute Kidney Injury prevalent or incident cases segmented by age, sex and subpopulations. The Report
Renal Cluster Drug Development Pipeline Review, 2017
ReportsWorldwide has announced the addition of a new report title Renal Cluster Drug Development Pipeline Review, 2017 to its growing collection of premium market research reports. This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and